About tisagenlecleucel
CD19-directed CAR T-cell immunotherapy
Used for
- B-cell acute lymphoblastic leukemia in eligible patients up to age 25
- Relapsed or refractory diffuse large B-cell lymphoma in adults
- Relapsed or refractory follicular lymphoma in adults
Usual adult dose
A single intravenous infusion; dose is individualized by body weight or cell count and indication.
Usual dose in children
For eligible patients up to age 25 with acute lymphoblastic leukemia, a single intravenous infusion; dose is individualized by body weight.
Common side effects
- Cytokine release syndrome
- Serious infections
- Nervous-system effects, including confusion or seizures
- Low blood-cell counts
Important warnings
- Requires specialist care and monitoring for potentially life-threatening reactions.
- Cytokine release syndrome may cause fever, low blood pressure, and breathing problems.
- Neurologic toxicity can be severe or life-threatening.
- Serious or fatal infections and prolonged low blood counts can occur.
Pregnancy
May harm a fetus; pregnancy status is checked before treatment. Effective contraception is advised during and after treatment as directed by the care team.
Breastfeeding
Breastfeeding is not recommended during treatment; when it may safely resume is unknown.
Interactions
- Live vaccines are generally avoided before, during, and after treatment until immune recovery.
- Medicines that suppress immune function may affect treatment; the specialist team reviews them.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.